US$4,650.00
May 2010
Global Cancer Biomarkers Market (2010 - 2015)
Cancer is recognized as a major cause of mortality world over; accounting for 7.4 million (or 13%) of all deaths in 2004. The WHO estimates the incidence of cancer to continue rising to reach an estimated 9.2 million deaths in 2015. The rising prevalence of the disease forms one of the major factors driving the growth of the oncology biomarkers market.
Order Now
|
More Information
|
Tell-a-Friend
US$3,500.00
Feb 2010
Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Costs
GBI Research's new report “Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Cost” provides an in-depth analysis on the potential applications of biomarkers in pharmaceutical drug discovery and clinical services. The report suggests investment decisions in biomarker based drug research by providing information on valid biomarkers, pipelines, case studies, competitive landscape, geographical dominance, mergers and acquisitions and market potential. It also provides an analysis on the trends prevailing in the global biomarkers market. In addition to this, the report also covers market drivers and Restrains for the global biomarkers market.
Order Now |
More Information |
Tell-a-Friend
US$2,224.00
Dec 2009
Global Pharmaceutical Biotech Market 2010-2025
The global pharmaceutical biotech market continues to experience high growth, with developers ranging from major pharmaceutical companies to specialist pharmaceutical firms. Significant R&D efforts and innovative new treatments will lead to further expansion of the pharma biotech market. This new report – Global Pharmaceutical Biotech Market 2010-2025 – explains why that market will expand, revealing where the most exciting developments will lie.
Order Now |
More Information |
Tell-a-Friend
US$3,400.00
Apr 2009
Companion Biomarkers in Drug Development
The term “companion biomarker” means that a particular diagnostic test is specifically linked to a therapeutic drug either in drug development or in the clinic. Biomarkers of disease have long played an important role in diagnostic medicine as evidenced by the intense use of specific clinical laboratory tests in the diagnosis of disease.
Order Now |
More Information |
Tell-a-Friend
US$3,400.00
Apr 2008
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. The purpose of this TriMark Publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. This study particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor’s offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer.
Order Now |
More Information |
Tell-a-Friend
US$3,835.00
Apr 2008
The Convergence of Biomarkers and Diagnostics:
Therapy area analyses, key products and future trends
‘The Convergence of Biomarkers and Diagnostics’ is a new report published by Business Insights that provides a detailed assessment of recent developments and future opportunities for biomarker companies in all major therapeutic areas. This report analyzes the markets for diagnostic biomarkers, including currently marketed products and products in development, and examines current trends in the discovery, validation and clinical application of biomarkers. Advances in biomarker detection technologies are profiled and the strategies of companies involved in biomarker discovery or diagnostic development are assessed. This report also forecasts growth in biomarker and diagnostic segments to 2012.
Order Now |
More Information |
Tell-a-Friend
